TherapeuticsMD Inc (TXMD) Shares Bought by C WorldWide Group Holding A S

TherapeuticsMD Inc (TXMD) Shares Bought by C WorldWide Group Holding A S

C WorldWide Group Holding A S lifted its position in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 41.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 989,834 shares of the company’s stock after purchasing an additional 287,959 shares during the period. C WorldWide Group Holding A S’s holdings in TherapeuticsMD were worth $4,820,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of TXMD. FMR LLC increased its position in shares of TherapeuticsMD by 50.1% during the fourth quarter. FMR LLC now owns 18,088,341 shares of the company’s stock worth $68,917,000 after purchasing an additional 6,038,353 shares in the last quarter. Millennium Management LLC increased its position in shares of TherapeuticsMD by 590.6% during the fourth quarter. Millennium Management LLC now owns 2,848,750 shares of the company’s stock worth $10,854,000 after purchasing an additional 2,436,259 shares in the last quarter. Frontier Capital Management Co. LLC acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth about $5,700,000. Vanguard Group Inc increased its position in TherapeuticsMD by 9.8% in the 3rd quarter. Vanguard Group Inc now owns 12,894,027 shares of the company’s stock valued at $84,585,000 after acquiring an additional 1,153,716 shares during the period. Finally, Vanguard Group Inc. increased its position in TherapeuticsMD by 9.8% in the 3rd quarter. Vanguard Group Inc. now owns 12,894,027 shares of the company’s stock valued at $84,585,000 after acquiring an additional 1,153,716 shares during the period. Institutional investors and hedge funds own 77.65% of the company’s stock.

In other TherapeuticsMD news, Director Jules A. Musing sold 17,400 shares of TherapeuticsMD stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $5.80, for a total value of $100,920.00. Following the sale, the director now owns 5,000 shares of the company’s stock, valued at approximately $29,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 22.85% of the stock is currently owned by insiders.

TXMD has been the topic of several recent research reports. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Tuesday. restated a “buy” rating and issued a $14.00 price target on shares of TherapeuticsMD in a research report on Tuesday, February 12th. Oppenheimer set a $14.00 price target on TherapeuticsMD and gave the company a “buy” rating in a research report on Monday, February 11th. ValuEngine cut TherapeuticsMD from a “buy” rating to a “hold” rating in a research report on Sunday, February 10th. Finally, Zacks Investment Research cut TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Thursday, February 28th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $12.75.

Shares of TXMD stock opened at $3.55 on Friday. The stock has a market capitalization of $890.11 million, a P/E ratio of -6.02 and a beta of 1.96. TherapeuticsMD Inc has a 52-week low of $3.45 and a 52-week high of $7.66. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.47 and a current ratio of 4.55.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Monday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. The firm had revenue of $3.95 million for the quarter, compared to analysts’ expectations of $5.96 million. TherapeuticsMD had a negative return on equity of 127.34% and a negative net margin of 823.71%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.11) EPS. As a group, equities research analysts forecast that TherapeuticsMD Inc will post -0.62 EPS for the current fiscal year.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Recommended Story: What is the Producer Price Index (PPI)?

Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).

Related posts

Leave a Comment